Open AccessNovel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
Author(s) -
Aaron C. Tan,
Tracy Jiezhen Loh,
Xue Lin Kwang,
Gek San Tan,
Kiat Hon Lim,
Daniel S.W. Tan
Publication year - 2021
Publication title -
lung cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.433
H-Index - 16
ISSN - 1179-2728
DOI - 10.2147/lctt.s263610
Subject(s) - medicine , exon , oncology , lung cancer , lung , cancer , cancer research , pathology , gene , genetics , biology
MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve and pre-treated settings and have led to regulatory approvals. This review will focus on practical diagnostic considerations for METex14 alterations, the trial evidence for capmatinib in this molecular subset including dosing and toxicity management, and the future therapeutic landscape of METex14 altered NSCLC.